Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University
What would be your next line of treatment for NSCLC adenocarcinoma that has recurred after chemoradiation with cis/etoposide?
PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?
Answer from: Medical Oncologist at Academic Institution
In this setting, it would depend upon the timing from completion of definitive chemoradiation and relapse/progression. In the absence of more definitive data, I take my cue from what most "first line" clinical trials have used for their eligibility criteria - patients are candidates (typically...
Sign in or Register to read more